All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the ALL Hub spoke to Joon Ho Moon, Kyungpook National University, Daegu, KR. We asked, How is relapsed/refractory ALL currently managed in Korea? Moon kindly gave his interview in Korean, with the title '한국의 재발성 및 불응성 급성림프구성백혈병의 치료'.
How is relapsed/refractory ALL currently managed in Korea? (KR)
In this video, Moon discusses the available therapy options used in Korea for patients with ALL, including immunotherapy, chemotherapy, and allogeneic transplantation.
Phase III study confirms superior outcomes using haploidentical donors in patients with pretransplant MRD-positive ALL
In this prospective, genetically randomized study (NCT02185261) recently published in Journal of Hematology & Oncology, Ying-Jun...
Treosulfan/fludarabine/thiotepa conditioning treatment before allogeneic hematopoietic stem cell transplantation for children with hematological malignancies
Results of a phase II, non-randomized, prospective study that evaluated the safety and...
Subscribe to get the best content related to ALL delivered to your inbox